Pardes Biosciences Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a novel direct-acting, oral antiviral drug candidate designed to treat SARS-CoV-2 infections, announced the completion of its business combination with FS Development Corp. II, a special purpose acquisition company (SPAC) sponsored by Foresite Capital.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, and Intouch Group, a full-service global agency network serving the pharmaceutical industry, announced that they signed an agreement to incorporate Intouch’s industry-leading creative and media services, enterprise solutions and data analytics into EVERSANA’s fully integrated commercialization services platform.
Med Ad News spoke with Mike Myers (managing director and partner of CrowdPharm and managing director and founder of Cross & Wild) and Steve Bernstein (CEO of Bernstein-Rein Advertising and CrowdPharm partner) about the combination of CrowdPharm and Cross & Wild, what makes CrowdPharm different from other agencies, and how they plan to expand the business in the future.
Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.
Immatics Biotechnologies GmbH entered into a definitive business combination agreement with Arya Sciences Acquisition Corp.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
